Running summarizing tools on a new article

Check the paper below, then start its synthesis.


Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset

Bin Lou (Qingdao University, First Affiliated Hospital Zhejiang University), Tingdong Li (Qingdao University, Xiamen University), Shufa Zheng (Qingdao University, First Affiliated Hospital Zhejiang University), Yingying Su (Qingdao University, Xiamen University), Zhiyong Li (Xiamen University), Wei Liu (Xiamen University, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics), Fei Yu (First Affiliated Hospital Zhejiang University, Zhejiang University), Shengxiang Ge (Xiamen University, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics), Qianda Zou (First Affiliated Hospital Zhejiang University, Zhejiang University), Quan Yuan (Xiamen University, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics), Sha Lin (First Affiliated Hospital Zhejiang University, Zhejiang University), Congming Hong (Xiamen University, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics), Xiangyang Yao (Xiamen University), Xue-Jie Zhang (Xiamen University, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics), Dinghui Wu (Xiamen University), Guoliang Zhou (Xiamen University, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics), Wangheng Hou (Xiamen University, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics), Tingting Li (Xiamen University, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics), Yali Zhang (Xiamen University, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics), Shiyin Zhang (Xiamen University, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics), Jian‐Gao Fan (First Affiliated Hospital Zhejiang University, State Key Laboratory of Diagnosis and Treatment of Infectious Diseases), Jun Zhang (Xiamen University, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics), Ningshao Xia (Xiamen University, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics), Yu Chen (First Affiliated Hospital Zhejiang University, State Key Laboratory of Diagnosis and Treatment of Infectious Diseases)

European Respiratory Journal
License: CC BY-NC

Abstract: BACKGROUND: Timely diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a prerequisite for treatment and prevention. The serology characteristics and complement diagnosis value of the antibody test to RNA test need to be demonstrated. METHOD: Serial sera of 80 patients with PCR-confirmed coronavirus disease 2019 (COVID-19) were collected at the First Affiliated Hospital of Zhejiang University, Hangzhou, China. Total antibody (Ab), IgM and IgG antibodies against SARS-CoV-2 were detected, and the antibody dynamics during the infection were described. RESULTS: The seroconversion rates for Ab, IgM and IgG were 98.8%, 93.8% and 93.8%, respectively. The first detectible serology marker was Ab, followed by IgM and IgG, with a median seroconversion time of 15, 18 and 20 days post exposure (d.p.e.) or 9, 10 and 12 days post onset (d.p.o.), respectively. The antibody levels increased rapidly beginning at 6 d.p.o. and were accompanied by a decline in viral load. For patients in the early stage of illness (0-7 d.p.o), Ab showed the highest sensitivity (64.1%) compared with IgM and IgG (33.3% for both; p<0.001). The sensitivities of Ab, IgM and IgG increased to 100%, 96.7% and 93.3%, respectively, 2 weeks later. When the same antibody type was detected, no significant difference was observed between enzyme-linked immunosorbent assays and other forms of immunoassays. CONCLUSIONS: A typical acute antibody response is induced during SARS-CoV-2 infection. Serology testing provides an important complement to RNA testing in the later stages of illness for pathogenic-specific diagnosis and helpful information to evaluate the adapted immunity status of patients.

Published on 19 May. 2020